IMMUNOGLOBULINS

DRUG15 trials

Sponsors

Alexion Pharmaceuticals Inc., Assistance Publique Hopitaux De Paris, Janssen Cilag International, Toleranzia AB, Nuvig Therapeutics Inc.

Conditions

Acquired Immunodeficiency SyndromeAdult patients with immune thrombocytopenia (ITP) with mild to severe bleeding manifestationsBlood TransfusionCIDPCOVID-19COVID-19 COVID-19 SARS-CoV2Chronic Inflammatory Demyelinating PolyneuropathyCytomegalovirus Infections

Phase 1

Dose scale-up and cohort expansion with the therapeutic mAb 14F7

Active, not recruitingRPCEC00000204

Center of Molecular Immunology (CIM)Solid tumors Solid tumors

Start: 2016-01-01Target: 60Updated: 2026-04-27

Anti SARS-CoV-2 gammaglobulin

Active, not recruitingRPCEC00000379

AICA Laboratorories CompanyCOVID-19 COVID-19 SARS-CoV2

Start: 2021-07-01Target: 30Updated: 2026-04-27

A double-blind, randomised, placebo-controlled, first-in-human (FIH) Phase I/IIa, multi-centre trial to assess safety, tolerability, and immune response of single and multiple ascending doses of TOL2 (Immune Tolerising Agent) in patients with generalised myasthenia gravis

Not yet recruitingCTIS2024-515627-10-00

Toleranzia ABgeneralised myasthenia gravis

Target: 42Updated: 2025-02-12

Phase 2

Immunoadsorption Versus Immunoglobulins for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

RecruitingNCT04881682

University of UlmCIDP

Start: 2023-05-01End: 2028-03-01Target: 20Updated: 2026-05-01

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immunoglobulin Stopping or Extension

RecruitingNCT05678621

Monash UniversityHaematological Malignancy, Hypogammaglobulinemia

Start: 2022-11-30End: 2027-04-30Target: 300Updated: 2024-04-19

Intravenous Immunoglobulin Replacement Therapy for Persistent COVID-19 in Patients With B-cell Impairment

RecruitingNCT06159283

Jaehoon KoCOVID-19

Start: 2024-03-18End: 2025-12-31Target: 58Updated: 2024-05-16

Pulse corticosteroids or/and Immunoglobulins to treat fulminant Myocarditis: a double-blind randomized controlled adaptive trial (The CORIUM study)

Not yet recruitingCTIS2023-506599-28-01

Assistance Publique Hopitaux De ParisFulminant myocarditis

Target: 120Updated: 2025-01-09

An Open-label, Intra-participant Dose Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of Intravenous NVG-2089 in Participants with Immune Thrombocytopenia

RecruitingCTIS2024-520359-26-00

Nuvig Therapeutics Inc.Immune Thrombocytopenia (ITP)

Start: 2025-08-20Target: 25Updated: 2025-09-04

Phase 3

Transfusion-Transmitted Cytomegalovirus Prevention in Neonates

CompletedNCT00000584

National Heart, Lung, and Blood Institute (NHLBI)Blood Transfusion, Cytomegalovirus Infections

Start: 1983-07-31End: 1988-06-30Updated: 2013-11-26

Anti-HIV Immunoglobulin (HIVIG) in Prevention of Maternal-Fetal HIV Transmission (Pediatric ACTG Protocol 185)

CompletedNCT00000590

National Heart, Lung, and Blood Institute (NHLBI)Acquired Immunodeficiency Syndrome, Disease Transmission, Vertical, HIV Infections

Start: 1991-09-30End: 1996-12-31Updated: 2016-04-14

Intravenous Immunoglobulin plus oral prednisone or high-dose dexamethasone, for adults with immune thrombocytopenia (ITP) with moderate and severe bleeding: a randomized, multicentre trial (IVIORDEX)

RecruitingCTIS2024-516403-16-00

Assistance Publique Hopitaux De ParisAdult patients with immune thrombocytopenia (ITP) with mild to severe bleeding manifestations

Start: 2022-04-07Target: 272Updated: 2025-05-27

Multicenter, Open-Label, Randomized Study of Nipocalimab or IVIG in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

RecruitingCTIS2023-509434-19-00

Janssen Cilag InternationalFetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

Start: 2025-02-10Target: 13Updated: 2026-01-21

PREV-CART - A multicentric phase III randomized clinical trial open-label, comparing immunoglobulin replacement therapy (IgRT) and antibiotic prophylaxis (AP) in patients treated by CD19-targeted Chimeric Antigen Receptor (CAR)T Cells for a B cell acute lymphoblastic leukemia or a B cell lymphoma

Not yet recruitingCTIS2025-521571-30-00

Assistance Publique Hopitaux De ParisYoung Adults and adults with R/R B-cell acute lymphoblastic leukemia (BCP-ALL) or a B cell lymphoma (BCL)

Target: 228Updated: 2026-04-13

Phase 4

An Interventional, Prospective Open-Label Study of Immunosuppressive Therapies to Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia (RESTORE)

CompletedCTIS2022-502793-17-00

Alexion Pharmaceuticals Inc.HYPOPHOSPHATASIA

End: 2025-08-08Target: 1Updated: 2024-09-19

Unknown Phase

Immunoglobulin Dosage and Administration Form in CIDP and MMN

CompletedNCT02111590

Rigshospitalet, DenmarkChronic Inflammatory Demyelinating Polyneuropathy, Hemolytic Anemia, Multifocal Motor Neuropathy

Start: 2014-01-31End: 2015-07-31Updated: 2015-09-22